UKALLXII/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

Blood

Volumn 123, Issue 6, 2014, Pages 843-850

  Fielding, Adele K ^a   Rowe, Jacob M ^b   Buck, Georgina ^c   Foroni, Letizia ^d   Gerrard, Gareth ^d   Litzow, Mark R ^e   Lazarus, Hillard ^f   Luger, Selina M ^g   Marks, David I ^h   McMillan, Andrew K ⁱ   Moorman, Anthony V ^j   Patel, Bella ^k   Paietta, Elisabeth ^j   Tallman, Martin S ^l   Goldstone, Anthony H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b RAMBAM MEDICAL CENTER   (Israel)

^c CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e MAYO CLINIC   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL HEALTH SERVICE   (United Kingdom)

ⁱ NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA REMISSION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; WHOLE BODY RADIATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BENZAMIDES; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84894066916     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-529008     Document Type: Article

References (16)

1. Moorman AV, Harrison CJ, Buck GA, et al; Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8): 3189-3197.
2. Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010;116(18):3409-3417.
3. de Labarthe A, Rousselot P, Huguet-Rigal F, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosomepositive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood. 2007;109(4): 1408-1413.
4. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103(12): 4396-4407.
5. Towatari M, Yanada M, Usui N, et al; Japan Adult Leukemia Study Group. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004; 104(12):3507-3512.
6. Ribera JM, Oriol A, González M, et al; Programa Espanol de Tratamiento en tologia; Grupo Espanol de Trasplante Hemopoy etico Groups. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95(1): 87-95.
7. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph1 ALL). Blood. 2006;108(5): 1469-1477.
8. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosomepositive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: Results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113(19):4489-4496.
9. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111 (4):1827-1833.
10. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 28(22): 3644-3652.
11. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol. 2009;27(31): 5175-5181.
12. Kebriaei P, Saliba R, Rondon G, et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012;18(4):584-592.
13. Pfeifer H, Wassmann B, Bethge W, et al; GMALL Study Group. Randomized comparison of prophylactic and minimal residual diseasetriggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6): 1254-1262.
14. Ram R, Storb R, Sandmaier BM, et al. Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96(8):1113-1120.
15. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366-374.
16. Mohty M, Labopin M, Volin L, et al; Acute Leukemia Working Party of EBMT. Reducedintensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22):4439-4443.